Sample Name
Sample Code
Sample Name
Sample Code
Sample Name
Sample Code
4
BIDU-SW
09888
5
JD HEALTH
06618
| (Q6)Jun 30, 2025 | (FY)Dec 31, 2024 | (Q6)Jun 30, 2024 | (FY)Dec 31, 2023 | (Q6)Jun 30, 2023 | (Q1)Mar 31, 2023 | (FY)Dec 31, 2022 | (Q9)Sep 30, 2022 | (Q1)Mar 31, 2022 | (FY)Dec 31, 2021 | |
|---|---|---|---|---|---|---|---|---|---|---|
| Turnover | 14.83%1.08B | 17.26%1.86B | 22.93%939.16M | 19.36%1.59B | --764M | 1.51%389.52M | 56.60%1.33B | 50.25%1.1B | --383.73M | 74.25%848.19M |
| Operating income | 14.83%1.08B | 17.26%1.86B | 22.93%939.16M | 19.36%1.59B | 764M | 1.51%389.52M | 56.60%1.33B | 50.25%1.1B | 383.73M | 74.25%848.19M |
| Cost of sales | -14.59%-664.5M | -7.95%-1.11B | -19.12%-579.91M | -25.22%-1.03B | ---486.83M | 7.77%-210.31M | -21.85%-823.07M | -36.46%-642.35M | ---228.02M | -29.07%-675.45M |
| Operating expenses | -14.59%-664.5M | -7.95%-1.11B | -19.12%-579.91M | -25.22%-1.03B | -486.83M | 7.77%-210.31M | -21.85%-823.07M | -36.46%-642.35M | -228.02M | -29.07%-675.45M |
| Gross profit | 15.22%413.93M | 34.55%746.38M | 29.62%359.25M | 9.80%554.7M | 277.17M | 15.09%179.21M | 192.46%505.2M | 74.98%459.4M | 155.71M | 572.53%172.74M |
| Selling expenses | -47.66%-63.44M | 38.75%-92.44M | 49.22%-42.97M | 36.74%-150.92M | ---84.61M | 47.46%-63.51M | 46.38%-238.57M | 42.32%-243.24M | ---120.88M | -33.09%-444.91M |
| Administrative expenses | -4.40%-139.12M | -18.72%-307.97M | -20.57%-133.25M | -3.06%-259.41M | ---110.52M | 6.74%-54.07M | -20.68%-251.7M | -32.96%-190.6M | ---57.98M | -48.90%-208.57M |
| Research and development expenses | 6.48%-190.34M | 20.76%-412.75M | 23.51%-203.53M | 11.16%-520.89M | ---266.09M | 11.97%-138.84M | 0.39%-586.33M | -4.33%-459.76M | ---157.72M | -32.45%-588.61M |
| Revaluation surplus | ---- | ---- | ---- | ---- | ---- | ---- | 145.58%16.97M | --16.97M | ---- | ---37.24M |
| -Changes in the fair value of investment property | ---- | ---- | ---- | ---- | ---- | ---- | 4,366.32%16.97M | --16.97M | ---- | --380K |
| -Changes in the fair value of other assets | ---- | ---- | ---- | ---- | ---- | ---- | ---- | ---- | ---- | ---37.62M |
| Impairment and provision | -110.05%-3.22M | -161.21%-4.66M | -165.22%-1.53M | -11.78%-1.78M | ---578K | -22.39%-913K | -54.65%-1.6M | 107.49%72K | ---746K | 97.63%-1.03M |
| -Other impairment is provision | -110.05%-3.22M | -161.21%-4.66M | -165.22%-1.53M | -11.78%-1.78M | ---578K | -22.39%-913K | -54.65%-1.6M | 107.49%72K | ---746K | 97.63%-1.03M |
| Special items of operating profit | 171.60%42.34M | -188.79%-102.56M | -347.67%-59.13M | -32.23%115.5M | --23.88M | -9.45%7.97M | 357.69%170.43M | 859.62%169.39M | --8.8M | 666.51%37.24M |
| Operating profit | 174.11%60.15M | 33.79%-174M | 49.51%-81.16M | 31.84%-262.8M | -160.75M | 59.41%-70.16M | 63.98%-385.6M | 65.90%-247.76M | -172.82M | -7.68%-1.07B |
| Financing cost | 131.95%1.83M | 66.47%-4.47M | 15.28%-5.74M | 42.15%-13.34M | ---6.78M | -57.61%-2.66M | -341.69%-23.07M | -114.82%-8.25M | ---1.69M | 84.47%-5.22M |
| Share of profits of associates | 85.00%-30K | ---215K | ---200K | ---- | ---- | ---- | ---- | ---- | ---- | 120.83%607K |
| Special items of earning before tax | ---- | -377.93%-2.28B | 5.95%-397.12M | 3.45%-476.16M | ---422.26M | -268.91%-270.81M | 32.65%-493.19M | 69.21%-227.36M | ---73.41M | -1,140.52%-732.28M |
| Earning before tax | 112.79%61.95M | -226.25%-2.45B | 17.90%-484.21M | 16.58%-752.31M | -589.79M | -38.60%-343.62M | 50.10%-901.85M | 67.09%-483.37M | -247.92M | -65.87%-1.81B |
| Tax | -88.79%225K | -70.55%978K | 6.92%2.01M | 81.57%3.32M | --1.88M | 111.19%1.57M | 345.50%1.83M | 26,130.00%2.6M | --742K | ---745K |
| After-tax profit from continuing operations | 112.89%62.17M | -227.56%-2.45B | 17.98%-482.21M | 16.78%-748.99M | -587.91M | -38.39%-342.06M | 50.22%-900.02M | 67.27%-480.77M | -247.18M | -65.94%-1.81B |
| After-tax profit from non-continuing business | ---- | 149.21%233.13M | 482.37%233.13M | 57.23%93.55M | --40.03M | ---- | 449.43%59.5M | ---- | ---- | ---17.03M |
| Earning after tax | 124.96%62.17M | -238.75%-2.22B | 54.54%-249.07M | 22.02%-655.44M | -547.88M | -38.39%-342.06M | 53.94%-840.53M | 67.27%-480.77M | -247.18M | -67.50%-1.83B |
| Minority shareholders should account for profits from continuing business | 62.30%-5.35M | 60.37%-25M | 59.73%-14.2M | -90.45%-63.08M | ---35.26M | ---- | 55.46%-33.12M | ---- | ---- | ---74.37M |
| Minority profit | 62.30%-5.35M | 60.37%-25M | 59.73%-14.2M | -90.45%-63.08M | ---35.26M | 26.29%-23.21M | 55.46%-33.12M | 68.58%-14.56M | ---31.49M | -426.54%-74.37M |
| Shareholders should account for profits from continuing business | 114.43%67.53M | -254.04%-2.43B | 15.32%-468.01M | 20.88%-685.91M | ---552.65M | ---- | 50.00%-866.9M | ---- | ---- | ---1.73B |
| Shareholders should account for profits from non-continuing business | ---- | 149.21%233.13M | 482.37%233.13M | 57.23%93.55M | --40.03M | ---- | 449.43%59.5M | ---- | ---- | ---17.03M |
| Profit attributable to shareholders | 128.75%67.53M | -270.60%-2.2B | 54.18%-234.88M | 26.63%-592.36M | -512.62M | -47.83%-318.85M | 53.88%-807.41M | 67.22%-466.21M | -215.69M | -62.79%-1.75B |
| Basic earnings per share | 117.78%0.08 | -251.33%-3.97 | 53.61%-0.45 | 26.62%-1.13 | -0.97 | -48.78%-0.61 | 58.15%-1.54 | 70.72%-0.89 | -0.41 | -71.16%-3.68 |
| Diluted earnings per share | 117.78%0.08 | -251.33%-3.97 | 53.61%-0.45 | 26.62%-1.13 | -0.97 | -48.78%-0.61 | 58.15%-1.54 | 70.72%-0.89 | -0.41 | -71.16%-3.68 |
| Currency Unit | CNY | CNY | CNY | CNY | CNY | CNY | CNY | CNY | CNY | CNY |
| Accounting Standards | IAS | IAS | IAS | IAS | IAS | IAS | IAS | IAS | IAS | IAS |
| Audit Opinions | -- | Unqualified Opinion | -- | Unqualified Opinion | -- | -- | Unqualified Opinion | -- | -- | Unqualified Opinion |
| Auditor | -- | KPMG | -- | KPMG | -- | -- | PwC accounting firm | -- | -- | PwC accounting firm |
FY: Financial Year. Refers to the 10-K file disclosed by the listed company to the SEC.
Q: Quarter. Refers to the 10-Q file disclosed by the listed company to the SEC. Q1, Q2, Q3, and Q4 are quarterly reports each with a span of 3 months; Q6 and Q9 are cumulative reports, with Q6 including 6 months and Q9 9 months.